---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-260785"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:48:35.587530+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics closes acquisition of EryDel for up to $485M in milestones

## Summary
- Issued 6,525,315 shares (15.2% ownership) to EryDel shareholders; up to 725,036 more shares at first anniversary.
- Contingent payments up to $485M: $5M development, $25M NDA acceptance, $60M approval, $395M sales milestones.
- Guarantees EryDel's EUR 30M EIB facility; ~EUR 10M drawn, maturity Aug 2026, fixed 9% interest.
- Appointed Luca Benatti as Class II director; granted option for 54,000 shares vesting over 3 years.

## SEC filing metadata
- accession: 0001193125-23-260785
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/0001193125-23-260785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/d562811d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-260785
- JSON: https://secwatch.observer/filing/0001193125-23-260785.json
- Plain text: https://secwatch.observer/filing/0001193125-23-260785.txt

## Key facts
- Debt Financings
  Quince Therapeutics, Inc. incurred credit facility of EUR 30,000,000 unsecured credit facility with European Investment Bank at 9.00% per annum maturing August 11, 2026.
  - Instrument: credit facility
  - Principal: EUR 30,000,000 unsecured credit facility
  - Counterparty: European Investment Bank
  - Rate: 9.00% per annum
  - Maturity: August 11, 2026
  - Event: incurrence
  source text: the “Quince Parties”), have agreed to guarantee the obligations of EryDel S.p.A, a company with shares incorporated under the laws of Italy (“EryDel”), in respect of a EUR 30,000,000 unsecured credit facility (the “EIB Facility”) evidenced by the Finance Contract, dated as of July 24, 2020 (the “Existing Finance Contract” and, as amended by the Amendment, the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/0001193125-23-260785-index.htm
- Executive change
  Luca Benatti was appointed as Director at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/0001193125-23-260785-index.htm
- M&A Transactions
  Quince Therapeutics, Inc. completed an acquisition involving EryDel S.p.A for 6,525,315 shares of common stock (closed 2023-10-20).
  - Action: acquisition
  - Counterparty: EryDel S.p.A
  - Consideration: 6,525,315 shares of common stock
  - Closing: 2023-10-20
  source text: company solely in its capacity as the representative, agent and attorney-in-fact of the EryDel Shareholders. Pursuant to the terms of the Purchase Agreement, the Company issued 6,525,315 shares of common stock of the Company to the EryDel Shareholders, resulting in the EryDel Shareholders owning approximately 15.2% of the outstanding common stock of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/0001193125-23-260785-index.htm
- Material Agreements
  Quince Therapeutics, Inc. entered into Finance Contract with European Investment Bank valued at EUR 30,000,000 (effective 2023-10-20).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: European Investment Bank
  - Value: EUR 30,000,000
  - Effective: 2023-10-20
  source text: the Finance Contract, dated as of July 24, 2020 (the “Existing Finance Contract” and, as amended by the Amendment, the “Amended Finance Contract”), by and between EryDel, as borrower, and the European Investment Bank, as lender (the “Lender”), by entering into (i) an Accession, Amendment and Restatement Agreement, dated as of October 20, 2023 (the “Amendment”), which amends and restates the Existing Finance Contract and joins each Quince Party thereto as a guarantor of the obligations of EryDel thereunder, and (ii) an Autonomous First Demand Guarantee ( Garanzia Autonoma a Prima Richiesta ) by each Quince Party respectively in favor of the Lender (collectively, the “Guarantees”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523260785/0001193125-23-260785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.